HK1137753A1 - Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists - Google Patents

Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists

Info

Publication number
HK1137753A1
HK1137753A1 HK10102651.4A HK10102651A HK1137753A1 HK 1137753 A1 HK1137753 A1 HK 1137753A1 HK 10102651 A HK10102651 A HK 10102651A HK 1137753 A1 HK1137753 A1 HK 1137753A1
Authority
HK
Hong Kong
Prior art keywords
pyrido
pyrimidin
derivatives
receptor antagonists
calcium receptor
Prior art date
Application number
HK10102651.4A
Other languages
English (en)
Inventor
Feng Bi
Mary Theresa Didiuk
David Andrew Griffith
Angel Guzman-Perez
Kevin Kun-Chin Liu
Daniel Patrick Walker
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of HK1137753A1 publication Critical patent/HK1137753A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK10102651.4A 2006-10-04 2010-03-15 Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists HK1137753A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82816206P 2006-10-04 2006-10-04
US96908307P 2007-08-30 2007-08-30
PCT/IB2007/002976 WO2008041118A2 (en) 2006-10-04 2007-09-26 Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists

Publications (1)

Publication Number Publication Date
HK1137753A1 true HK1137753A1 (en) 2010-08-06

Family

ID=39183043

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10102651.4A HK1137753A1 (en) 2006-10-04 2010-03-15 Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists

Country Status (17)

Country Link
US (2) US7829572B2 (xx)
EP (1) EP2079739A2 (xx)
JP (1) JP2010505811A (xx)
KR (1) KR101129868B1 (xx)
CN (1) CN101547922B (xx)
AR (1) AR063122A1 (xx)
AU (1) AU2007303846B2 (xx)
CA (1) CA2663436A1 (xx)
CL (1) CL2007002864A1 (xx)
HK (1) HK1137753A1 (xx)
IL (1) IL197536A0 (xx)
MX (1) MX2009003673A (xx)
NO (1) NO20091328L (xx)
PE (1) PE20081455A1 (xx)
TW (1) TW200822929A (xx)
UY (1) UY30620A1 (xx)
WO (1) WO2008041118A2 (xx)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8845672B2 (en) 2002-05-09 2014-09-30 Reshape Medical, Inc. Balloon system and methods for treating obesity
US20070100368A1 (en) 2005-10-31 2007-05-03 Quijano Rodolfo C Intragastric space filler
US8226602B2 (en) * 2007-03-30 2012-07-24 Reshape Medical, Inc. Intragastric balloon system and therapeutic processes and products
US8142469B2 (en) 2007-06-25 2012-03-27 Reshape Medical, Inc. Gastric space filler device, delivery system, and related methods
US9174031B2 (en) * 2009-03-13 2015-11-03 Reshape Medical, Inc. Device and method for deflation and removal of implantable and inflatable devices
US8683881B2 (en) * 2009-04-03 2014-04-01 Reshape Medical, Inc. Intragastric space fillers and methods of manufacturing including in vitro testing
CN101619063B (zh) * 2009-06-02 2011-08-10 华中师范大学 具有抗肿瘤活性的3,7,8-多取代吡啶并[4,3-d]嘧啶衍生物及制备
US9358143B2 (en) 2009-07-22 2016-06-07 Reshape Medical, Inc. Retrieval mechanisms for implantable medical devices
WO2011011743A2 (en) 2009-07-23 2011-01-27 Reshape Medical, Inc. Deflation and removal of implantable medical devices
US9604038B2 (en) 2009-07-23 2017-03-28 Reshape Medical, Inc. Inflation and deflation mechanisms for inflatable medical devices
EP2533845A4 (en) 2010-02-08 2016-04-06 Reshape Medical Inc IMPROVED AND REINFORCED EXTRACTION METHOD AND MECHANISMS FOR INTRAGASTRAL DEVICES
US9149611B2 (en) 2010-02-08 2015-10-06 Reshape Medical, Inc. Materials and methods for improved intragastric balloon devices
EP2539011A4 (en) 2010-02-25 2014-03-26 Reshape Medical Inc IMPROVED AND REINFORCED EXPLANT PROCESSES AND MECHANISMS FOR INTRAGASTRAL DEVICES
WO2011127205A1 (en) 2010-04-06 2011-10-13 Reshape Medical , Inc. Inflation devices for intragastric devices with improved attachment and detachment and associated systems and methods
WO2012011591A1 (ja) * 2010-07-23 2012-01-26 武田薬品工業株式会社 縮合複素環化合物およびその用途
EP2413139B1 (en) 2010-07-30 2015-05-20 Universität Leipzig Method and compositions for the identification of agents that have a potential effect against chronic inflammatory diseases
EP2683697B1 (en) 2011-03-10 2017-09-06 Lupin Atlantis Holdings SA Substituted morpholines as modulators for the calcium sensing receptor
CA2829466A1 (en) 2011-03-18 2012-09-27 Lupin Limited Benzo [b] [1,4] oxazin derivatives as calcium sensing receptor modulators
PT3738434T (pt) 2011-12-28 2023-11-13 Global Blood Therapeutics Inc Intermediários para obter compostos de benzaldeído substituído e métodos para a sua utilização no aumento da oxigenação de tecidos
ES2790358T3 (es) 2011-12-28 2020-10-27 Global Blood Therapeutics Inc Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular
PE20142281A1 (es) 2012-02-24 2015-01-16 Lupin Ltd Compuestos de cromano sustituidos como moduladores del receptor sensible al calcio
WO2013136288A1 (en) 2012-03-16 2013-09-19 Lupin Limited Substituted 3,4-dihydro-2h-benzo[b] [1,4]oxazine compounds as calcium sensing receptor modulators
IN2015MN00421A (xx) 2012-08-27 2015-09-04 Lupin Ltd
CN111454200A (zh) 2013-03-15 2020-07-28 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
CA2902711C (en) 2013-03-15 2021-07-06 Global Blood Therapeutics, Inc. Substituted pyridinyl-6-methoxy-2-hydroxybenzaldehyde derivatives and pharmaceutical compositions thereof useful for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
SG10201802911RA (en) 2013-03-15 2018-05-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
ITTO20130430A1 (it) * 2013-05-28 2014-11-29 Illinois Tool Works Dispositivo per il pre-riscaldamento ad induzione e la saldatura testa a testa di lembi adiacenti di almeno un elemento da saldare
TW201602062A (zh) 2013-08-12 2016-01-16 魯賓有限公司 取代聯苯基化合物作為鈣敏感受體調節劑
AU2014313835A1 (en) 2013-08-28 2016-03-03 Lupin Atlantis Holdings Sa Substituted naphthalene compounds as calcium sensing receptor modulators
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
SI3102208T1 (sl) 2014-02-07 2021-07-30 Global Blood Therapeutics, Inc. Kristalinični polimorf proste baze 2-hidroksi-6-((2-(1-izopropil-1H-pirazol-5-IL)piridin-3-IL)metoksi)- benzaldehida
WO2015162538A1 (en) 2014-04-21 2015-10-29 Lupin Limited Heterocyclic compounds as calcium sensing receptor modulators for the treatment of hyperparathyroidism, chronic renal failure and chronic kidney disease
US10244588B2 (en) * 2014-10-14 2019-03-26 Illinois Tool Works Inc. Hybrid induction heating/welding assembly
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
WO2017037616A1 (en) 2015-08-31 2017-03-09 Lupin Limited Arylalkylamine compounds as calcium sensing receptor modulators
MA43373A (fr) 2015-12-04 2018-10-10 Global Blood Therapeutics Inc Régimes posologiques pour 2-hydroxy-6-((2- (1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)méthoxy)benzaldéhyde
TWI752307B (zh) 2016-05-12 2022-01-11 美商全球血液治療公司 新穎化合物及製造化合物之方法
TWI778983B (zh) 2016-10-12 2022-10-01 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
CN108164455A (zh) * 2017-03-23 2018-06-15 广东众生药业股份有限公司 马来酸非尼拉敏的合成方法
CN107903209B (zh) * 2017-12-29 2021-05-14 宁夏忠同生物科技有限公司 一种2-氨基-5-氟吡啶-3-甲酸甲酯的合成方法
US11014884B2 (en) 2018-10-01 2021-05-25 Global Blood Therapeutics, Inc. Modulators of hemoglobin
KR102338609B1 (ko) * 2019-05-20 2021-12-14 보령제약 주식회사 피리도-피리미딘 화합물 및 이를 유효성분으로 포함하는 pi3k 관련 질환의 예방 또는 치료용 약학적 조성물
AU2020415502A1 (en) 2019-12-27 2022-07-14 Lupin Limited Pharmaceutical composition of CaSR modulators and methods and uses thereof
CA3166512A1 (en) 2020-01-17 2021-07-22 Lupin Limited Methods, processes and intermediates for preparing chroman compounds
CN113956268B (zh) * 2021-11-19 2022-07-15 西安欧得光电材料有限公司 一种6-溴-1-氯苯并噻吩[2,3-c]吡啶及合成方法

Family Cites Families (201)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US646572A (en) * 1899-03-15 1900-04-03 Archibald C Floyd Bath-cabinet.
CH624395A5 (xx) * 1976-01-08 1981-07-31 Ciba Geigy Ag
US4343940A (en) 1979-02-13 1982-08-10 Mead Johnson & Company Anti-tumor quinazoline compounds
EP0054132B1 (de) * 1980-12-12 1984-10-10 Dr. Karl Thomae GmbH Neue Pyrimidinone, ihre Herstellung und Arzneimittel mit einem Gehalt an diesen Stoffen
US4422711A (en) 1981-12-21 1983-12-27 Amp Incorporated Active pin contact
US4431440A (en) * 1981-02-20 1984-02-14 American Cyanamid Company Method to alter or control the development and/or the life cycle of various plant species
US4588812A (en) * 1984-05-30 1986-05-13 Pennwalt Corporation Substituted 2,3-dihydro-5H-thiazolo[2,3,-b]quinazoline derivatives
GB8429739D0 (en) * 1984-11-24 1985-01-03 Fbc Ltd Fungicides
GB8513754D0 (en) 1985-05-31 1985-07-03 Jones T R Anti-cancer quinazoline derivatives
GB8811435D0 (en) * 1988-05-13 1988-06-15 Ici Plc Fungicides
EP0370629B2 (en) 1988-11-21 1998-01-07 Zeneca Limited Fungicides
GB8827988D0 (en) 1988-11-30 1989-01-05 Smith Kline French Lab Chemical compounds
IE62559B1 (en) * 1989-02-02 1995-02-08 Ici Plc Fungicides
US5145856A (en) 1989-02-10 1992-09-08 Imperial Chemical Industries Plc Fungicides
BE1003002A6 (fr) 1989-03-21 1991-10-22 Coppe Jan Composition a mettre en oeuvre pour le traitement de la calvitie, et procedes faisant usage de celle-ci.
GB8914797D0 (en) * 1989-06-28 1989-08-16 Ici Plc Fungicides
US5240928A (en) 1989-07-03 1993-08-31 Merck & Co., Inc. Substituted quinazolinones as angiotensin II antagonists
US5187779A (en) * 1989-08-11 1993-02-16 Micral, Inc. Memory controller with synchronous processor bus and asynchronous i/o bus interfaces
GB9016783D0 (en) 1989-09-01 1990-09-12 Ici Plc Agrochemical compositions
GB8928547D0 (en) * 1989-12-18 1990-02-21 Ici Plc Fungicides
HU206680B (en) 1989-12-22 1992-12-28 Ici Plc Fungicide compositions containing pyridyl-cyclopropane-amides as active components and process for producing the active components
GB9000130D0 (en) * 1990-01-04 1990-03-07 Ici Plc Fungicides
US5264439A (en) 1990-02-13 1993-11-23 Merck & Co., Inc. Quinazolinone, triazolinone and pyrimidinone angiotensin II antagonists incorporating a substituted benzyl element
CA2037630C (en) * 1990-03-07 2001-07-03 Akira Morimoto Nitrogen-containing heterocylic compounds, their production and use
GB9012017D0 (en) * 1990-05-30 1990-07-18 Ici Plc Fungicidal compounds
GB9013615D0 (en) 1990-06-19 1990-08-08 Wellcome Found Pharmaceutical compounds
US5225318A (en) * 1990-07-02 1993-07-06 Ocg Microelectronic Materials, Inc. Selected photoactive methylolated cyclohexanol compounds and their use in forming positive resist image patterns
IE74711B1 (en) * 1990-07-27 1997-07-30 Ici Plc Fungicides
GB9016578D0 (en) 1990-07-27 1990-09-12 Ici Plc Fungicides
GB9016584D0 (en) * 1990-07-27 1990-09-12 Ici Plc Fungicides
GB9018408D0 (en) 1990-08-22 1990-10-03 Ici Plc Fungicides
US5110471A (en) * 1990-08-30 1992-05-05 Conoco Specialty Products Inc. High efficiency liquid/liquid hydrocyclone
GB9023294D0 (en) 1990-10-25 1990-12-05 Ici Plc Fungicides
US5290780A (en) * 1991-01-30 1994-03-01 American Cyanamid Co. Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
US5385894A (en) * 1991-03-06 1995-01-31 Merck & Co., Inc. Disubstituted 6-aminoquinazolinones
NZ242290A (en) 1991-04-15 1994-12-22 Zeneca Ltd Pyridyl and pyrimidinyl substituted oxime-o-benzyl ether derivatives; preparatory processes, fungicidal compositions and an intermediate
US5252574A (en) 1991-04-26 1993-10-12 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted thiophene or furan
WO1992020642A1 (en) * 1991-05-10 1992-11-26 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5162325A (en) 1991-05-07 1992-11-10 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted benzyl element
US5158953A (en) 1991-08-13 1992-10-27 National Science Council 2-substituted methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-ones (thiones), the preparation and use thereof
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
DE4130298A1 (de) 1991-09-12 1993-03-18 Basf Ag Fungizide mischungen
GB9126260D0 (en) * 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
DE4243340A1 (de) * 1992-12-21 1994-06-23 Sued Chemie Ag Sorptionsmittel
US5420133A (en) * 1993-03-19 1995-05-30 Merck & Co., Inc. Quinazolinones substituted with phenoxyphenylacetic acid derivatives
US5401745A (en) * 1993-03-19 1995-03-28 Merck & Co., Inc. Quinazolinones substituted with phenoxyphenylacetic acid derivatives
ATE136734T1 (de) 1993-09-24 1996-05-15 Basf Ag Fungizide mischungen
US5721236A (en) * 1993-10-15 1998-02-24 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
JP3364727B2 (ja) * 1993-10-22 2003-01-08 イハラケミカル工業株式会社 ２，２−ビス（３，５−ジ置換−４−ヒドロキシフェニル）プロパン誘導体とその製造方法およびこの誘導体を用いるピロガロールの製造法
US5464854A (en) * 1993-11-11 1995-11-07 Depadova; Anathony S. Method of modifying ovarian hormone-regulated AT1 receptor activity as treatment of incapacitating symptom(s) of P.M.S.
US5756502A (en) * 1994-08-08 1998-05-26 Warner-Lambert Company Quinazolinone derivatives as cholyecystokinin (CCK) ligands
ATE287390T1 (de) * 1994-10-21 2005-02-15 Nps Pharma Inc Kalzium-rezeptor aktive verbindungen
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
GB9423911D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
DE19501481A1 (de) * 1995-01-19 1996-07-25 Bayer Ag 2,8-Disubstituierte Chinazolinone
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
MY115814A (en) 1995-06-16 2003-09-30 Bayer Ip Gmbh Crop protection compositions
EP0844818B1 (de) 1995-08-17 1999-09-22 Basf Aktiengesellschaft Fungizide mischungen eines oximethercarbonsäureamids mit azolderivaten
US6897213B1 (en) 1995-11-21 2005-05-24 Warner-Lambert Company Heterocycles as cholecystokinin (CCK) ligands
JPH09241110A (ja) * 1996-03-08 1997-09-16 Sumitomo Chem Co Ltd 殺菌剤組成物
KR100432454B1 (ko) * 1996-04-26 2005-04-08 바스프 악티엔게젤샤프트 살진균제 혼합물
WO1997040674A1 (de) * 1996-04-26 1997-11-06 Basf Aktiengesellschaft Fungizide mischung
DE69722613T2 (de) 1996-05-15 2004-05-13 Pfizer Inc. 2,3,6-trisubstituierte 4(3h)-chinazolinone
AU3766897A (en) * 1996-07-13 1998-02-09 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
DE19629825A1 (de) 1996-07-24 1998-01-29 Bayer Ag Dihydrofuran-carboxamide
US6110471A (en) 1996-09-13 2000-08-29 The Board Of Trustees Of The Leland Stanford Junior University Non-hormonal method of contraception
US6225318B1 (en) * 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
DK0964860T3 (da) * 1997-02-28 2004-07-26 Pfizer Prod Inc Atropisomerer af 3-heteroaryl-4-(3H)-quinazolinoner til behandling af neurodegenerative og CNS-trauma-relaterede tilstande
NZ336628A (en) 1997-02-28 2001-03-30 Pfizer Prod Inc Atropisomers of 3-aryl-4(3H)-quinazolinones and their use as AMPA-receptor antagonists
US5948775A (en) * 1997-03-19 1999-09-07 American Home Products Corporation 2- or 3-(substitutedaminoalkoxyphenyl)quinazolin-4-ones
FR2762841B1 (fr) * 1997-04-30 1999-07-02 Jouveinal Inst Rech Diazepino-indolones inhibitrices de phosphodiesterases iv
CO5050364A1 (es) 1997-05-28 2001-06-27 Basf Ag Metodo para controlar hongos nocivos
US6369090B1 (en) * 1997-06-04 2002-04-09 Basf Aktiengesellschaft Fungicidal mixture
US6060479A (en) * 1997-06-09 2000-05-09 Pfizer Inc Quinazoline-4-one AMPA antagonists
US6627755B1 (en) 1997-06-09 2003-09-30 Pfizer Inc Quinazolin-4-one AMPA antagonists
US5753851A (en) * 1997-06-16 1998-05-19 The United States Of America As Represented By The Secretary Of The Army Spinning mine with concentrated projectiles
EP0900567A3 (en) 1997-09-05 2001-05-02 Pfizer Products Inc. Quinazoline-4-one AMPA antagonists for the treatment of dyskinesias associated with dopamine agonist therapy
IL125950A0 (en) 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
US20030069231A1 (en) 1999-10-12 2003-04-10 Klaus Rudolf Modified aminoacids, pharmaceuticals containing these compounds and method for their production
JP2959765B2 (ja) * 1997-12-12 1999-10-06 日本たばこ産業株式会社 ３−ピペリジル−４−オキソキナゾリン誘導体及びそれを含有してなる医薬組成物
TW431861B (en) * 1997-12-18 2001-05-01 Basf Ag Fungicidal mixtures based on amide compounds and azoles
GB9800569D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
EP1051176B1 (en) * 1998-01-27 2006-11-22 Aventis Pharmaceuticals Inc. SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS
JPH11279158A (ja) 1998-02-09 1999-10-12 Pfizer Prod Inc キナゾリン―４―オン誘導体の製造方法
JPH11228643A (ja) * 1998-02-17 1999-08-24 Menicon Co Ltd 眼用レンズ材料およびその製法
WO1999044612A1 (en) 1998-03-02 1999-09-10 Cocensys, Inc. Substituted quinazolines and analogs and the use thereof
US6337332B1 (en) * 1998-09-17 2002-01-08 Pfizer Inc. Neuropeptide Y receptor antagonists
US6187779B1 (en) * 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6225315B1 (en) * 1998-11-30 2001-05-01 Pfizer Inc Method of treating nitrate-induced tolerance
GB9828340D0 (en) 1998-12-22 1999-02-17 Novartis Ag Organic compounds
US6270781B1 (en) * 1999-01-08 2001-08-07 Maxim Pharmaceuticals, Inc. Method and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors
DE19911509A1 (de) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
FR2792938B1 (fr) 1999-04-28 2001-07-06 Warner Lambert Co NOUVELLES 1-AMINO TRIAZOLO [4,3-a] QUINAZOLINE-5-ONES INHIBITRICES DE PHOSPHODIESTERASES IV
JP4831906B2 (ja) * 1999-08-27 2011-12-07 ケモセントリックス， インコーポレイテッド Ｃｘｃｒ３機能を調節するための複素環式化合物および方法
US7060706B1 (en) * 1999-09-28 2006-06-13 3-Dimensional Pharmaceuticals, Inc. Quinazolinones
US6890930B1 (en) * 1999-09-28 2005-05-10 3-Dimensional Pharmaceuticals, Inc. Quinazolinones
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US6562830B1 (en) * 1999-11-09 2003-05-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl quinazolinone derivatives
US6664390B2 (en) 2000-02-02 2003-12-16 Warner-Lambert Company Llc Method for the simplified production of (3-chloro-4-fluorophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-nitro-quinazoline-4-yl]-amine or (3-chloro-4-fluorophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-amino-quinazoline-4-yl]-amine
US6697213B2 (en) * 2000-03-31 2004-02-24 Seagate Technology Llc Cover including multiple cover plates with damped layers
EP1365806A2 (en) 2000-04-19 2003-12-03 Johns Hopkins University Use of no acttivators for treatment and prevention of gastrointestinal disorders
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
KR100785363B1 (ko) * 2000-04-25 2007-12-18 이코스 코포레이션 인간 포스파티딜-이노시톨 3-키나제 델타의 억제제
US6916956B2 (en) * 2000-08-11 2005-07-12 Japan Tobacco, Inc. Calcium receptor antagonist
EP1188438A1 (en) 2000-09-15 2002-03-20 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production
AU2001293817A1 (en) * 2000-09-20 2002-04-02 Merck Patent Gmbh 4-amino-quinazolines
AU2001292936A1 (en) * 2000-09-22 2002-04-02 Ortho-Mcneil Pharmaceutical, Inc. Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines
WO2002030470A1 (en) * 2000-10-13 2002-04-18 Johns Hopkins University Methods and compositions for nucleic acid delivery
EP1404654A4 (en) * 2000-10-25 2008-12-03 Smithkline Beecham Corp CALCILYTIC COMPOUNDS
IL156304A0 (en) 2000-12-11 2004-01-04 Tularik Inc Cxcr3 antagonists
US6900220B2 (en) * 2001-01-02 2005-05-31 Syntex (U.S.A.) Llc Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists
HUP0303249A3 (en) 2001-02-22 2007-03-28 Sankyo Co Water-soluble triazole fungicide compounds and pharmaceutical compositions containing them
EP1396488A1 (en) 2001-05-23 2004-03-10 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
JP4523271B2 (ja) * 2001-06-01 2010-08-11 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼのインヒビターとして有用なチアゾール化合物
US7220777B2 (en) * 2001-10-15 2007-05-22 Smithkline Beecham P.L.C. Lactam derivatives as antagonists for human 11cby receptors
AU2002363429B2 (en) 2001-11-07 2008-05-08 Merck & Co., Inc. Mitotic kinesin inhibitors
US20040110777A1 (en) * 2001-12-03 2004-06-10 Annis Gary David Quinazolinones and pyridinylpyrimidinones for controlling invertebrate pests
WO2003062209A2 (en) * 2002-01-17 2003-07-31 Neurogen Corporation Substituted quinazolin-4-ylamine analogues as modulators of capsaicin
CA2475879A1 (en) * 2002-02-15 2003-08-28 Cytokinetics, Inc. Synthesis of quinazolinones
US6559293B1 (en) 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
JP2005524695A (ja) 2002-04-26 2005-08-18 アルタナ　ファルマ　アクチエンゲゼルシャフト 呼吸機能不全を治療するためのグアニル酸シクラーゼ活性化剤の新規の使用
JP4681302B2 (ja) 2002-05-06 2011-05-11 バーテックス ファーマシューティカルズ インコーポレイテッド チアジアゾールまたはオキサジアゾール、およびこれらの、ｊａｋプロテインキナーゼのインヒビターとしての使用
US7214800B2 (en) * 2002-05-09 2007-05-08 Cytokinetics, Inc. Compounds, compositions, and methods
WO2003103575A2 (en) * 2002-05-23 2003-12-18 Cytokinetics, Inc. Compounds, compositions, and methods
CA2485343A1 (en) * 2002-05-23 2004-05-13 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2003099818A1 (en) * 2002-05-23 2003-12-04 Chiron Corporation Substituted quinazolinone compounds
EP1537089A4 (en) * 2002-07-23 2008-04-16 Cytokinetics Inc CONNECTIONS, COMPOSITIONS AND PROCEDURES
US20040048853A1 (en) 2002-08-21 2004-03-11 Gustave Bergnes Compounds, compositions, and methods
US20040242572A1 (en) 2002-08-24 2004-12-02 Boehringer Ingelheim International Gmbh New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture
WO2004034972A2 (en) 2002-09-30 2004-04-29 Cytokinetics, Inc. Compounds, compositions, and methods
CA2500727A1 (en) 2002-10-03 2004-04-15 Targegen, Inc. Vasculostatic agents and methods of use thereof
GB0223730D0 (en) * 2002-10-11 2002-11-20 Novartis Ag Organic compounds
AU2003301662A1 (en) * 2002-10-21 2004-05-13 Bristol-Myers Squibb Company Quinazolinones and derivatives thereof as factor xa inhibitors
WO2004041755A2 (en) * 2002-11-04 2004-05-21 Nps Pharmaceuticals, Inc. Quinazolinone compounds as calcilytics
FR2846657B1 (fr) * 2002-11-05 2004-12-24 Servier Lab Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP4695395B2 (ja) * 2002-12-13 2011-06-08 ニューロジェン・コーポレーション 疼痛治療用の併用療法
GB0230015D0 (en) * 2002-12-23 2003-01-29 Novartis Ag Organic compounds
US7407962B2 (en) 2003-02-07 2008-08-05 Vertex Pharmaceuticals Incorporated Heteroaryl compounds useful as inhibitors or protein kinases
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
CL2004000409A1 (es) 2003-03-03 2005-01-07 Vertex Pharma Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
WO2004081009A1 (en) 2003-03-12 2004-09-23 Millennium Pharmaceuticals, Inc. Quinazoline derivatives as tgf-beta inhibitors
WO2004084973A2 (en) * 2003-03-24 2004-10-07 Becton, Dickinson And Company Invisible antimicrobial glove and hand antiseptic
US7687625B2 (en) 2003-03-25 2010-03-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2004085382A1 (ja) 2003-03-27 2004-10-07 Kirin Beer Kabushiki Kaisha 生体内リン輸送を阻害する化合物およびそれを含んでなる医薬
WO2004087153A2 (en) * 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
WO2004092121A2 (en) * 2003-04-07 2004-10-28 Nps Pharmaceuticals, Inc. Methods for preparing 2,3,5,6-substituted 3h-pyrimidin-4-ones
US20070161792A1 (en) * 2003-04-07 2007-07-12 Nps Pharmacueticals, Inc Methods for preparing 2,3,5,6-substituted 3h-pyrimidin-4-ones
ES2359451T3 (es) * 2003-04-07 2011-05-23 Nps Pharmaceuticals, Inc. Compuestos de pirimidona en calidad de calcilíticos.
GB0309009D0 (en) * 2003-04-22 2003-05-28 Astrazeneca Ab Quinazoline derivatives
NZ544040A (en) * 2003-05-22 2009-03-31 Nycomed Gmbh Composition comprising a PDE4 inhibitor and a PDE5 inhibitor
EP1651229A1 (en) * 2003-05-23 2006-05-03 Chiron Corporation Guanidino-substituted quinazolinone compounds as mc4-r agonists
WO2004106308A1 (en) 2003-05-27 2004-12-09 Pfizer Products Inc. Quinazolines and pyrido [3,4-d] pyrimidines as receptor tyrosine kinase inhibitors
ATE459359T1 (de) 2003-06-06 2010-03-15 Arexis Ab Verwendung von kondensierten heterozyklischen verbindungen als scce-hemmern zur behandlung von hautzuständen
US20050038051A1 (en) * 2003-06-09 2005-02-17 Jodi Nunnari Novel molecules for regulating cell death
US7238664B2 (en) 2003-06-16 2007-07-03 Altana Pharma Ag Composition comprising a pulmonary surfactant and a PDE5 inhibitor for the treatment of lung diseases
WO2005002585A1 (en) * 2003-07-02 2005-01-13 Warner-Lambert Company Llc Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
CA2530312A1 (en) * 2003-07-02 2005-01-20 F. Hoffmann-La Roche Ag Arylamine-substituted quinazolinone compounds
AU2004253967B2 (en) * 2003-07-03 2010-02-18 Cytovia, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
WO2005016348A1 (en) 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
JP2007512230A (ja) * 2003-08-20 2007-05-17 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼ阻害剤として有用な（４−アミノ−１，２，５−オキサジアゾール−４−イル）−ヘテロ芳香族化合物
JP5335191B2 (ja) * 2003-08-22 2013-11-06 デンドレオン コーポレイション Ｔｒｐ−ｐ８発現に関連する疾患の処置をするための組成物および方法
US20050059862A1 (en) * 2003-09-12 2005-03-17 Scimed Life Systems, Inc. Cannula with integrated imaging and optical capability
JP2007505873A (ja) * 2003-09-16 2007-03-15 アストラゼネカ アクチボラグ チロシンキナーゼ阻害剤としてのキナゾリン誘導体
US20050059851A1 (en) * 2003-09-17 2005-03-17 Vincent Ardizzone Flexible magnetic pad with multi-directional constantly alternating polarity zones
TW200524892A (en) 2003-09-24 2005-08-01 Glaxo Group Ltd Calcilytic compounds
GB0325175D0 (en) * 2003-10-28 2003-12-03 Novartis Ag Organic compounds
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
US7368453B2 (en) 2003-11-19 2008-05-06 Chiron Corporation Quinazolinone compounds with reduced bioaccumulation
NZ547327A (en) * 2003-11-21 2009-08-28 Array Biopharma Inc AKT protein kinase inhibitors
ATE521341T1 (de) 2003-12-01 2011-09-15 Kudos Pharm Ltd Dna-schäden-reparatur-hemmer zur behandlung von krebs
EP1696927A4 (en) * 2003-12-19 2007-10-31 Merck & Co Inc MITOTIC INHIBITORS OF KINESIN
AU2004303876A1 (en) * 2003-12-19 2005-07-07 Merck & Co., Inc. Mitotic kinesin inhibitors
US20050136085A1 (en) * 2003-12-19 2005-06-23 David Bellamy Panthenol and natural organic extracts for reducing skin irritation
CA2552664A1 (en) 2004-01-08 2005-07-28 Michigan State University Methods for treating and preventing hypertension and hypertension-related disorders
EP1711504A2 (en) 2004-01-21 2006-10-18 Molecular Probes Inc. Derivatives of cephalosporin and clavulanic acid for detecting beta-lactamase in a sample
UA83416C2 (xx) 2004-02-13 2008-07-10 Баниу Фармасьютикал Ко., Лтд. Конденсоване 4-оксопіримідинове похідне$конденсированное 4-оксопиримидиновое производное
DE602005017135D1 (de) 2004-03-05 2009-11-26 Nycomed Gmbh Neue verwendung von pde5-hemmern
US7462612B2 (en) 2004-03-26 2008-12-09 Vertex Pharmaceuticals Incorporated Pyridine inhibitors of ERK2 and uses thereof
WO2005102342A1 (en) 2004-04-22 2005-11-03 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for the treatment of sexual disorders ii
JP2007536239A (ja) * 2004-05-06 2007-12-13 スミスクライン・ビーチャム・コーポレイション カルシウム受容体アンタゴニスト化合物
CA2730540A1 (en) * 2004-05-13 2005-12-01 Vanderbilt University Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
CA2567883A1 (en) * 2004-05-25 2005-12-15 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic cells
US20070232607A1 (en) 2004-06-04 2007-10-04 Bradbury Robert H Quinazoline Derivatives as Erbb Receptor Tyrosine kinases
US7429604B2 (en) * 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
US7939538B2 (en) * 2004-06-28 2011-05-10 Amgen Inc. Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases
TW200605430A (en) * 2004-07-20 2006-02-01 Avision Inc Electrical magnetic interference inspecting system
US7203079B2 (en) * 2004-07-23 2007-04-10 System General Corp. Switching controller having frequency hopping for power supplies
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
US7718658B2 (en) * 2004-09-02 2010-05-18 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
WO2006034196A1 (en) * 2004-09-17 2006-03-30 Lifelike Biomatic Inc. Compositions for enhancing memory and methods therefor
US8011027B2 (en) * 2004-11-17 2011-09-06 Interspiro, Inc. Protective seal mechanism
JP2006151028A (ja) * 2004-11-25 2006-06-15 Sumitomo Rubber Ind Ltd タイヤとリムとの組立体およびこれに用いるサポートリング
US7466645B2 (en) * 2004-12-21 2008-12-16 Panasonic Corporation OFDM signal receiving apparatus
US20070032506A1 (en) * 2005-07-02 2007-02-08 Peter Giannousis Crystalline forms of (2r-trans)-6-chloro-5[[4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-n,n, 1-trimethyl-alpha-oxo-1h-indole-3-acetamide monohydrochloride
KR20080077652A (ko) * 2005-12-22 2008-08-25 알콘 리서치, 리미티드 로 키나제-매개 질환 및 증상 치료용 (인다졸-5-일)피라진및 (1,3-디하이드로인돌-2-온)피라진
TWI338846B (en) * 2006-12-22 2011-03-11 Univ Nat Pingtung Sci & Tech A method for grid-based data clustering
EP1964548A1 (en) 2007-03-02 2008-09-03 Novartis AG Pharmaceutical compositions comprising a calcilytic agent
CA2747417C (en) * 2009-01-08 2017-01-03 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease

Also Published As

Publication number Publication date
WO2008041118A3 (en) 2008-10-23
AR063122A1 (es) 2008-12-30
WO2008041118A2 (en) 2008-04-10
CN101547922B (zh) 2012-06-20
UY30620A1 (es) 2008-05-31
CN101547922A (zh) 2009-09-30
KR20090074066A (ko) 2009-07-03
AU2007303846A1 (en) 2008-04-10
NO20091328L (no) 2009-05-04
TW200822929A (en) 2008-06-01
US20110028452A1 (en) 2011-02-03
MX2009003673A (es) 2009-04-22
PE20081455A1 (es) 2008-10-18
CL2007002864A1 (es) 2008-04-04
IL197536A0 (en) 2009-12-24
AU2007303846B2 (en) 2011-03-10
JP2010505811A (ja) 2010-02-25
US20080085887A1 (en) 2008-04-10
CA2663436A1 (en) 2008-04-10
KR101129868B1 (ko) 2012-04-12
EP2079739A2 (en) 2009-07-22
US7829572B2 (en) 2010-11-09

Similar Documents

Publication Publication Date Title
HK1137753A1 (en) Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
HK1140200A1 (en) Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
ZA200800353B (en) Pyrazine derivatives useful as adenosine receptor antagonists
ZA201004823B (en) Novel pyrazolo [3,4-d]pyrimidine derivatives as anti-cancer agents
EG25765A (en) Pyrido [2,3-B] pyrazine derivatives useful as herbicidal compounds
ZA201004524B (en) Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
TWI372751B (en) Pyrimidines as prostaglandin d2 receptor antagonists
ZA201003050B (en) [1h- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or pyridin-2-yle derivatives as protein kinase c-theta
IL199015A0 (en) Quinuclidinol derivatives as muscarinic receptor antagonists
IL188478A0 (en) Indol-3-carbonyl-spiro-piperidine derivatives as v1a receptor antagonists
IL186881A (en) Pyrido derivatives [3,2– d] pyrimidine and their uses for the manufacture of drugs against hcv
HK1126204A1 (en) Substituted bicyclic pyrimidone derivatives
HUP0600858A2 (en) Piperizinyilpiperidine derivatives as chemokine receptor antagonists
EP2139332A4 (en) SUBSTITUTED PYRIDO [2,3-D] PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS
ZA201101861B (en) Compositions with and process for methylmorpholin-substituted pyrido [2,3-d] pyrimidines
PL2079711T3 (pl) Pochodne 2-fenylo-6-aminokarbonylopirymidyny i ich zastosowanie jako antagonistów receptora P2Y12
PL2020410T3 (pl) Pochodne pirydo[2,3-d]pirymidyny, ich wytwarzanie i zastosowanie terapeutyczne
PL1912976T3 (pl) Pochodne indol-3-ilokarbonylopiperydynobenzoimidazolu jako antagoniści receptora V1a
HUP0501169A2 (en) New phenantridine derivatives as selective bradykinin b1 receptor antagonists
ZA200803658B (en) 2-amino-7,8-dihydro-6H-pyrido[4,3-d] pyrimidin-5-ones
IL198544A0 (en) Spiro-piperidine derivatives as via receptor antagonists
ZA201105257B (en) 3-(3-pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyrimidine derivatives
IL188724A0 (en) NEW PYRIDO[3',2':4,5]FURO[3,2-d]PYRIMIDINE DERIVATIVES
EP2351756A4 (en) SUBSTITUTED 3-ARYLSULFONYL-PYRAZOLO [1,5-A] PYRIMIDINES, SEROTONIN-5-HT6 RECEPTOR ANTAGONISTS, AND METHOD FOR THEIR PREPARATION AND USE
ZA200800516B (en) Indol-3-yl-carbonyl-piperidin-benzoimidazol derivatives as V1a receptor antagonists

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20160926